Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 118

1.

Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer.

Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET.

Integr Cancer Ther. 2018 Dec;17(4):1103-1108. doi: 10.1177/1534735418803755. Epub 2018 Oct 5.

2.

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM.

J Clin Oncol. 2018 May 20;36(15):1498-1504. doi: 10.1200/JCO.2017.76.4126. Epub 2018 Apr 6.

PMID:
29624463
3.

The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.

Maccini MA, Westfall NJ, Van Bokhoven A, Lucia MS, Poage W, Maroni PD, Wilson SS, Glodé LM, Arangua P, Newmark J, Steiner M, Werahera PN, Crawford ED.

Prostate. 2018 May;78(7):506-511. doi: 10.1002/pros.23495. Epub 2018 Feb 19.

PMID:
29460452
4.

Man With Locally Advanced, High-Risk Prostate Cancer Asks About Adding Chemotherapy to His Treatment.

Bourlon MT, Mora M, Hinojosa-Fano J, Martínez-Benitez B, Amini A, Castillejos-Molina R, Glodé LM.

Oncology (Williston Park). 2016 Jan;30(1):94-8. No abstract available.

5.

Progress in Prostate Cancer (at Last!).

Glodé LM.

Oncology (Williston Park). 2015 Jun;29(6):407, 414. No abstract available.

6.

Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[(18)F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts.

Schlaepfer IR, Glodé LM, Hitz CA, Pac CT, Boyle KE, Maroni P, Deep G, Agarwal R, Lucia SM, Cramer SD, Serkova NJ, Eckel RH.

Mol Imaging Biol. 2015 Aug;17(4):529-38. doi: 10.1007/s11307-014-0814-4.

7.

Base of the skull metastases in metastatic castration-resistant prostate cancer.

Bourlon MT, Glodé LM, Crawford ED.

Oncology (Williston Park). 2014 Dec;28(12):1115-6, 1124. No abstract available.

8.

Lipid catabolism via CPT1 as a therapeutic target for prostate cancer.

Schlaepfer IR, Rider L, Rodrigues LU, Gijón MA, Pac CT, Romero L, Cimic A, Sirintrapun SJ, Glodé LM, Eckel RH, Cramer SD.

Mol Cancer Ther. 2014 Oct;13(10):2361-71. doi: 10.1158/1535-7163.MCT-14-0183. Epub 2014 Aug 13.

9.

Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.

Lam ET, Glodé LM.

Hematol Oncol Clin North Am. 2013 Dec;27(6):1189-204, viii. doi: 10.1016/j.hoc.2013.08.004. Epub 2013 Sep 21. Review.

PMID:
24188258
10.

Nonseminomatous germ cell tumor of testis and interrupted treatment.

Glodé LM, Lam E.

Oncology (Williston Park). 2013 Aug;27(8):822-3. No abstract available.

11.

Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.

Beer TM, Schellhammer PF, Corman JM, Glodé LM, Hall SJ, Whitmore JB, Frohlich MW, Penson DF.

Urology. 2013 Aug;82(2):410-5. doi: 10.1016/j.urology.2013.04.049.

PMID:
23896100
12.

Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer.

Dorff TB, Glode LM.

Curr Opin Urol. 2013 Jul;23(4):366-71. doi: 10.1097/MOU.0b013e328361d467. Review.

13.

Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.

Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW.

Clin Cancer Res. 2013 Jan 1;19(1):148-57. doi: 10.1158/1078-0432.CCR-12-1258. Epub 2012 Nov 21.

14.

Trends in twitter use by physicians at the american society of clinical oncology annual meeting, 2010 and 2011.

Chaudhry A, Glodé LM, Gillman M, Miller RS.

J Oncol Pract. 2012 May;8(3):173-8. doi: 10.1200/JOP.2011.000483. Epub 2012 Apr 17.

15.

Proliferative tumor doubling times of prostatic carcinoma.

Werahera PN, Glode LM, La Rosa FG, Lucia MS, Crawford ED, Easterday K, Sullivan HT, Sidhu RS, Genova E, Hedlund T.

Prostate Cancer. 2011;2011:301850. doi: 10.1155/2011/301850. Epub 2011 Sep 21.

16.

A rare case of metastatic renal epithelioid angiomyolipoma.

Lam ET, La Rosa FG, Suby-Long TD, Kondo KL, Wilson S, Glodé LM, Flaig TW.

Oncology (Williston Park). 2011 Aug;25(9):832-8. No abstract available.

17.

Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.

Clemons J, Glodé LM, Gao D, Flaig TW.

Urol Oncol. 2013 Feb;31(2):198-204. doi: 10.1016/j.urolonc.2010.12.004. Epub 2011 Jul 27.

18.

Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.

Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, Frohlich MW.

Clin Cancer Res. 2011 Jul 1;17(13):4558-67. doi: 10.1158/1078-0432.CCR-10-3223. Epub 2011 May 10.

19.

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM.

J Clin Oncol. 2011 May 20;29(15):2040-5. doi: 10.1200/JCO.2010.32.2776. Epub 2011 Apr 18.

20.

Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer.

Amato RJ, Glode LM, Podolnick J, Knight R, Crawford D.

Cancers (Basel). 2011 Sep 2;3(3):3449-60. doi: 10.3390/cancers3033449.

Supplemental Content

Loading ...
Support Center